zortress: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0414-20	60 BLISTER PACK in 1 BOX (0078-0414-20) / 1 TABLET in 1 BLISTER PACK (0078-0414-61)	2010-04-22
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0415-20	60 BLISTER PACK in 1 BOX (0078-0415-20) / 1 TABLET in 1 BLISTER PACK (0078-0415-61)	2010-04-22
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0417-20	60 BLISTER PACK in 1 BOX (0078-0417-20) / 1 TABLET in 1 BLISTER PACK (0078-0417-61)	2010-04-22
Novartis	ZORTRESS	everolimus	TABLET;ORAL	021560	NDA	Novartis Pharmaceuticals Corporation	0078-0422-20	60 BLISTER PACK in 1 BOX (0078-0422-20) / 1 TABLET in 1 BLISTER PACK (0078-0422-61)	2010-04-22
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 31, 2025

Introduction

ZORTRESS (everolimus) is an immunosuppressant medication primarily prescribed to prevent organ rejection post-renal and hepatic transplantation. As a derivative of rapamycin (sirolimus), everolimus functions by inhibiting mammalian target of rapamycin (mTOR), thus suppressing immune responses. Since its approval by the FDA in 2009, ZORTRESS has grown into a critical component of transplant medicine. Ensuring a reliable supply chain for ZORTRESS involves understanding the key suppliers involved in manufacturing its active pharmaceutical ingredient (API), formulation, packaging, and distribution.

This analysis delves into the global suppliers playing vital roles across the ZORTRESS supply chain, examining manufacturing footprints, regulatory certifications, and market dynamics to assist industry stakeholders in strategic decision-making.

Manufacturers of Everolimus API

The cornerstone of ZORTRESS supply hinges on the availability of high-quality, GMP-compliant everolimus API. Several multinational pharmaceutical companies and specialty chemical suppliers produce this API, either directly for GSK (the original developer and marketer of ZORTRESS) or for third-party pharmaceutical manufacturers.

1. Novartis (via Sandoz)

While Novartis originally developed the molecule, Sandoz (a Novartis division) manufactures generic versions of everolimus. Sandoz's facilities in Europe and the US are equipped with state-of-the-art GMP manufacturing capabilities. They supply APIs compliant with stringent international standards, including FDA and EMA certifications, essential for global distribution. Their emphasis on quality control ensures API purity levels exceeding 99%, critical for immunosuppressant drugs.

2. Hikma Pharmaceuticals

Hikma, a leading generics manufacturer based in Jordan, licenses and produces the API for various immunosuppressant drugs, including everolimus. Their manufacturing units in Europe, particularly in Portugal and the UK, adhere to GMP standards, and they cater to both the US and European markets by supplying high-grade APIs conforming to pharmacopeial specifications.

3. Dr. Reddy’s Laboratories

This Indian pharmaceutical giant produces a range of APIs, including everolimus, through facilities in India with GMP certifications recognized by US FDA and EMA. Dr. Reddy’s APIs are distributed globally, and the company maintains strict quality assurance processes to meet international standards for immunosuppressants.

4. Aurobindo Pharma

With manufacturing bases across India, Aurobindo Pharma produces everolimus API for the generics market. Their facilities meet leading regulatory standards, enabling them to supply bulk API for generic formulations of ZORTRESS across various jurisdictions.

5. Mylan (now part of Viatris)

Mylan has a long history of producing immunosuppressive APIs, including everolimus, with facilities in India and Europe. Their production complies with cGMP guidelines, allowing them to serve major markets with both branded and generic drug components.

Formulation and Final Product Manufacturing

Beyond API supply, the formulation of ZORTRESS involves several manufacturing partners specializing in finished dose forms, primarily oral tablets. While GSK manufactures ZORTRESS for exclusive supply, several contract manufacturing organizations (CMOs) are involved in formulation, packaging, and distribution.

1. GSK’s Manufacturing Facilities

GSK (GlaxoSmithKline) oversees the production of ZORTRESS at its approved manufacturing sites worldwide, notably in Europe and North America. These facilities hold comprehensive regulatory approvals, ensuring consistent quality and supply. GSK maintains strict quality controls, including stability testing, to adhere to global standards.

2. Contract Manufacturing Organizations (CMOs)

GSK partners with multiple CMOs to meet global demand:

Hetero Labs (India): Known for oral solid-dose manufacturing, Hetero supplies GSK with finished ZORTRESS tablets.
Samsung BioLogics (South Korea): While primarily known for biologics, Samsung partners with GSK for certain formulations and packaging.

These partnerships allow GSK to scale production efficiently while maintaining high standards and regulatory compliance.

Distribution and Supply Chain Management

The distribution of ZORTRESS involves a complex web of global logistics, including warehousing, transportation, and inventory management. GSK’s distribution network spans over 100 countries, collaborating with various distributors and specialty pharmacies.

Key players include:

McKesson Corporation: Supplies U.S. hospitals and clinics, ensuring timely delivery.
WWL (World Wide Logistics): Handles international shipping and customs clearance.
Local wholesalers and specialty pharmacy chains: Manage on-the-ground distribution, especially in emerging markets.

Effective supply chain management is crucial to prevent shortages, given the drug's critical role in transplant medicine.

Market Dynamics Influencing Supplier Choice

The landscape for ZORTRESS suppliers is shaped by factors such as patent status, market exclusivity, manufacturing capacity, and regulatory hurdles.

Patent Status: GSK’s patent protections have delayed generic entry in some markets. Once patents expire, an influx of generic API manufacturers increases competition.
Regulatory Approvals: Suppliers with approved manufacturing facilities under US FDA, EMA, and other major authorities hold a competitive advantage.
Manufacturing Capacity: Reliable, high-volume facilities are preferred due to the high demand for transplant immunosuppressants.
Pricing and Market Share: Generics offer cost advantages, compelling original developers like GSK to prioritize multiple API sources to mitigate supply disruptions and competitive pressures.

Regulatory and Quality Considerations

API suppliers and CMOs must adhere to highly regulated standards:

Good Manufacturing Practice (GMP): Certified facilities with quality control measures aligned with FDA, EMA, or other global standards.
Pharmacopoeial Compliance: APIs must meet specifications in contexts like the US Pharmacopeia (USP) or European Pharmacopoeia (EP).

GSK’s procurement process emphasizes supplier audits, batch testing, and stability data to ensure the quality and safety of ZORTRESS.

Conclusion

The supply of ZORTRESS is supported by a narrow but globally distributed network of API manufacturers, key manufacturing partners, and logistics providers. Major API producers include Novartis/Sandoz, Hikma, Dr. Reddy’s, Aurobindo, and Viatris (formerly Mylan), each playing a vital role in ensuring continuous availability. GSK’s internal manufacturing, complemented by external CMOs, fortifies the supply chain, emphasizing quality, compliance, and scalability. Ongoing patent litigations and market entries of generics will influence supplier dynamics and market competition moving forward.

Key Takeaways

The core API for ZORTRESS is produced by several GMP-compliant manufacturers, including Novartis/Sandoz, Hikma, Dr. Reddy’s, Aurobindo, and Viatris.
GSK’s manufacturing facilities and trusted CMOs are critical for formulation and packaging, impacting global availability.
Regulatory compliance and high manufacturing standards are crucial for suppliers, especially given the drug’s critical role in transplant patient care.
Diversification of API sources reduces risk of supply disruptions amid patent expirations and increasing generic competition.
Logistics and distribution partnerships ensure timely delivery, particularly in emerging markets.

FAQs

1. Who are the leading API suppliers for ZORTRESS?
Major API suppliers include Novartis/Sandoz, Hikma Pharmaceuticals, Dr. Reddy’s Laboratories, Aurobindo Pharma, and Viatris. These companies meet global GMP standards to supply high-quality everolimus API.

2. What is the role of GSK in the ZORTRESS supply chain?
GSK manufactures the finished ZORTRESS tablets at approved facilities, collaborates with CMOs for formulation and packaging, and manages global distribution networks.

3. Are there generic versions of ZORTRESS available?
Yes. Multiple generics containing everolimus are available in various markets, produced by companies like Sandoz, Aurobindo, and others, often leveraging their own or licensed APIs.

4. How does patent expiration impact suppliers?
Patent expirations open the market to additional API manufacturers, increasing supply options and potentially reducing costs through competition.

5. What should stakeholders consider when assessing ZORTRESS supply risks?
Key factors include verifying supplier GMP compliance, regulatory approvals, manufacturing capacity, redundancy of sources, and stability of distribution channels to ensure uninterrupted supply.

References

[1] U.S. Food and Drug Administration. ZORTRESS (Everolimus) Prescribing Information.
[2] European Medicines Agency. ZORTRESS Summary of Product Characteristics.
[3] IMS Health Reports. Global Market for Immunosuppressants.
[4] GSK Annual Report 2022. Pharmaceutical Manufacturing & Supply Chain Overview.
[5] Pharmaceutical Technology. "API Manufacturing Trends in Immunosuppressants."

Suppliers and packagers for zortress

zortress

Suppliers for the Pharmaceutical Drug: ZORTRESS (Everolimus)